Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

The purpose of this study is to determine whether or not XL184 demonstrates anti-tumor
activity in selected tumor types under a randomized discontinuation trial (RDT) design.
Subjects who have responded to study drug after 12 weeks of open-label XL184 administration
will continue to take XL184. Subjects who are clearly progressing will discontinue study
treatment and subjects who demonstrate stable disease will be randomized to either XL184 or
placebo. For individual patients, once disease progression is observed, the blind will be
broken and subjects who were randomized to placebo will be offered the option to receive
open-label XL184. Subjects who progressed while taking XL184 will discontinue study
treatment.

Emerging data may support enrollment in an open-label, non-randomized expansion cohort
(NRE). Subjects with prostate and ovarian cancers will enroll in these expansion cohorts.
Other tumor types may similarly be expanded, as supporting data emerges. Not all clinical
sites will be participating in the expansion cohorts; some sites may not enroll subjects
with prostate or ovarian cancer.

Due to the nature of the study design, enrollment to certain tumor type cohorts may open and
close.